Obesity - HealthQuill

Denmark’s Novo Nordisk will advance its experimental drug amycretin, in both injection and oral forms, into end-stage trials in weight management based on completed clinical studies, according to a company statement.

Novo Nordisk’s obesity drug to begin end-stage trials in early 2026

HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.

by HealthQuill
June 13, 2025
0 Comments

Denmark’s Novo Nordisk A/S and US-based Deep Apple Therapeutics Inc. signed an $812 million agreement to develop an oral small molecule targeting cardiometabolic diseases, such as obesity.

Climate Health Research

Novo Nordisk in $812m pact with Deep Apple for oral small molecule

HQ Team June 11, 2025: Denmark’s Novo Nordisk A/S and US-based Deep Apple Therapeutics Inc. signed an $812 million agreement to develop an.

by HealthQuill
June 11, 2025
0 Comments

Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products for diabetes and other chronic diseases.

Drugs Health Pharma

Lilly, Sweden’s Camurus sign $870 million pact for incretin products

HQ Team June 4, 2025: Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products.

by HealthQuill
June 4, 2025
0 Comments

Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for a weight-loss drug candidate.

Drugs Health Pharma

Regeneron to pay China’s Hansoh $80m upfront for weight-loss drug

HQ Team June 2, 2025: Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for.

by HealthQuill
June 3, 2025
0 Comments

Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor that may cure chronic pain without using opioids.

Drugs Health Pharma

Novo Nordisk, Septerna in $2.2b deal to develop oral molecules

HQ Team May 14, 2025: Novo Nordisk and Septerna, Inc., have inked a $2.2 billion global collaboration and licensing pact to develop oral.

by HealthQuill
May 14, 2025
0 Comments

Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a drug-induced liver injury that was resolved after discontinuation of the oral drug.

Uncategorized

Pfizer stops development of an investigational drug to treat obesity

HQ Team April 15, 2025: Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a.

by HealthQuill
April 15, 2025
0 Comments

Novo Nordisk will invest 6.4 billion reais ($1.05 billion) in Brazil’s Monte Claros to expand its production of injectable treatments for people living with obesity and chronic diseases.

Drugs Medical Pharma

Novo Nordisk to invest $1.05b in Monte Claros facility in Brazil

HQ Team April 10, 2025: Novo Nordisk will invest 6.4 billion reais ($1.05 billion) in Brazil’s Monte Claros to expand its production of.

by HealthQuill
April 10, 2025
0 Comments

Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and commercialising of the Chinese company’s “triple G” weight-loss candidate.

Drugs Medical Pharma

Novo Nordisk in $2b deal with Chinese firm for ‘triple-G’ obesity drug

HQ Team February 25, 2025: Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and.

by HealthQuill
March 25, 2025
0 Comments

Obesity is a health risk that needs to be tackled worldwide

Health Medical

Weight loss offers health benefits, even if pounds creep back: Study

Bharti Jayshankar March 24, 2025: University of Gothenburg researchers have uncovered a silver lining for those who struggle to maintain weight loss. According.